Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Maziar Mike Doustdar will take the helm as CEO tomorrow, with the firm facing tough questions from investors about how it can stay competitive.

Danish pharma giant Novo Nordisk reports 32% rise in Q2 net profit to $4.1B, driven by strong sales of Ozempic and Wegovy ...

The Danish drug maker reiterated its full-year outlook after last week slashing its guidance on weaker second-half U.S. sales ...